What Is the GigaAssay™ and Why It’s the Future of Precision Medicine
Precision medicine is reshaping healthcare, and the GigaAssay™ is leading the revolution. At EthicaMeds, we developed the GigaAssay™ to address one major flaw in traditional cancer treatment: lack of individualized data. Unlike conventional genetic tests that detect known mutations, the GigaAssay™ assesses millions of genetic variations simultaneously. Powered by the Genomic Multiplex Library (GML), this platform evaluates how these mutations affect protein activity, gene regulation, and drug response in living cells. This real-world, functional testing ensures that HER2+ breast cancer patients receive treatments proven to be effective based on their unique genetics. Instead of predicting outcomes theoretically, we deliver empirical, actionable results. For breast cancer patients, this technology means faster, safer, and more effective treatments. For clinicians, it provides the clarity needed to prescribe with confidence. The GigaAssay™ is not just innovation; it’s the future standard for precision oncology, and EthicaMeds is leading the way.
From Diagnosis to Delivery: How EthicaMeds Puts Patients First
At EthicaMeds, our philosophy is simple yet revolutionary: put patients first. Traditional healthcare often relies on population-wide averages, neglecting the genetic differences that dictate treatment success. Using advanced genetic technologies like GigaAssay™ and the Genomic Multiplex Library (GML), EthicaMeds tailors breast cancer treatment to the patient’s unique genetic makeup. Before prescribing, we analyze millions of genetic mutations to predict how the patient will respond to HER2+ therapies. But analysis is only the beginning. EthicaMeds delivers personalized medicines designed to match each patient’s genetic profile. We screen over 20,000 biologic variants to ensure optimal efficacy, significantly improving survival rates and quality of life for breast cancer patients. This approach minimizes trial-and-error prescribing, sparing patients from unnecessary side effects. By aligning treatment with real genetic data, EthicaMeds redefines what ethical, effective healthcare should be. When it comes to fighting breast cancer, patients deserve better. EthicaMeds ensures they get it — from diagnosis to delivery.
Why 75% of Cancer Drugs Fail — And How Personalized Medicine Can Change That
In today’s oncology landscape, a critical problem persists: approximately 75% of cancer drugs fail to deliver benefits due to genetic mismatches. Despite medical advancements, many treatments are prescribed without considering a patient’s unique genetic profile. Patients endure harsh side effects with little therapeutic gain. Traditional medicine has a flaw — it treats diseases based on broad population data. Yet, each patient’s genetics can determine whether a drug will be effective, especially in cases like HER2+ breast cancer. At EthicaMeds, we are transforming cancer treatment through personalized medicine. Our proprietary GigaAssay™ technology tests the functional impact of millions of genetic variants, including the full spectrum of 5,886 HER2+ mutations. Unlike conventional tests, we assess how a patient’s unique genetic profile responds in real-world environments. This precision approach means we can predict with near 100% accuracy which cancer drugs won’t work, saving time, reducing suffering, and increasing survival odds. With over 112 newly identified breast cancer-associated mutations, EthicaMeds ensures no genetic detail is overlooked. Personalized medicine isn’t just a trend — it’s the ethical, effective future of healthcare. EthicaMeds is proud to lead the charge, ensuring every breast cancer patient receives the right treatment based on their individual genetics.
